Platelet Count Monitoring and Laboratory Testing for Heparin-Induced Thrombocytopenia
Open Access
- 1 November 2002
- journal article
- Published by Archives of Pathology and Laboratory Medicine in Archives of Pathology & Laboratory Medicine
- Vol. 126 (11) , 1415-1423
- https://doi.org/10.5858/2002-126-1415-pcmalt
Abstract
Objective.—Heparin-induced thrombocytopenia (HIT) is an antibody-mediated adverse drug reaction that paradoxically is associated with a brief but dramatically increased risk for thrombosis (transient acquired thrombophilia). The objective of this article is to provide practical recommendations for platelet count monitoring in patients receiving heparin, as well as for selection of laboratory assays to detect pathogenic HIT antibodies. Study Selection.—Relevant literature that focused on frequency and timing of HIT in various clinical settings and that dealt with laboratory testing for HIT antibodies was critically appraised. Data Extraction and Synthesis.—The author prepared a preliminary manuscript including recommendations that was presented to participants at the College of American Pathologists Conference XXXVI: Diagnostic Issues in Thrombophilia (November 10, 2001). Support of at least 70% of conference participants was required for recommendations to be adopted. Conclusions.—The risk of immune HIT varies depending on the type of heparin (unfractionated heparin greater than low-molecular-weight heparin) and patient population (surgical greater than medical). Thus, the intensity of platelet count monitoring should be stratified depending on the clinical situation. Platelet count monitoring should focus on the period of highest risk (usually days 5 to 10 after starting heparin) and should use an appropriate platelet count baseline (generally, the highest platelet count beginning 4 days after start of heparin). However, earlier platelet count monitoring is appropriate if the patient received heparin within the past 100 days, as already circulating HIT antibodies can cause rapid-onset HIT with heparin reexposure. Although both antigen and (washed platelet) activation assays are very sensitive for detecting clinically significant HIT antibodies, activation assays have greater diagnostic specificity for clinical HIT.Keywords
This publication has 48 references indexed in Scilit:
- Nonimmune Heparin–Platelet Interactions: Implications for the Pathogenesis of Heparin-Induced ThrombocytopeniaPublished by Taylor & Francis ,2007
- Heparin-Dependent Antigens in Heparin-Induced ThrombocytopeniaPublished by Taylor & Francis ,2003
- Generation of platelet-derived microparticles and procoagulant activity by heparin-induced thrombocytopenia IgG/serum and other IgG platelet agonists: a comparison with standard platelet agonistsPlatelets, 1999
- A diagnostic test for heparin‐induced thrombocytopenia: detection of platelet microparticles using flow cytometryBritish Journal of Haematology, 1996
- Pathogenicity of IgA and/or IgM antibodies to heparin–PF4 complexes in patients with heparin‐induced thrombocytopeniaBritish Journal of Haematology, 1996
- Heparin‐induced skin lesionsBritish Journal of Haematology, 1996
- Heparin-Induced Thrombocytopenia in Patients Treated with Low-Molecular-Weight Heparin or Unfractionated HeparinNew England Journal of Medicine, 1995
- Laboratory diagnosis of heparin‐associated thrombocytopenia and comparison of platelet aggregation test, heparin‐induced platelet activation test, and platelet factor 4/heparin enzyme‐linked immunosorbent assayTransfusion, 1994
- Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells.Journal of Clinical Investigation, 1994
- Heparin - induced thrombocytopenia: laboratory investigation and confirmation of diagnosisPathology, 1992